Detalhe da pesquisa
1.
CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
Br J Cancer;
123(7): 1101-1113, 2020 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32684628
2.
In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer.
EMBO Mol Med;
14(4): e14608, 2022 04 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34927798